More recently, the treatment options for metastatic pancreatic adenocarcinomas have increased with the approval of nab-paclitaxel (albumin-bound paclitaxel) as first line therapy in combination with gemcitabine [10]. Here, ALB is linked to pancreatic adenocarcinoma.